EP0568631A4 - Anticorps monoclonaux destines a un recepteur de surface cellulaire (elam-1) et utilisations de ces derniers. - Google Patents
Anticorps monoclonaux destines a un recepteur de surface cellulaire (elam-1) et utilisations de ces derniers.Info
- Publication number
- EP0568631A4 EP0568631A4 EP92905123A EP92905123A EP0568631A4 EP 0568631 A4 EP0568631 A4 EP 0568631A4 EP 92905123 A EP92905123 A EP 92905123A EP 92905123 A EP92905123 A EP 92905123A EP 0568631 A4 EP0568631 A4 EP 0568631A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- elam
- monoclonal antibodies
- monoclonal
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64587891A | 1991-01-24 | 1991-01-24 | |
US645878 | 1991-01-24 | ||
US73303391A | 1991-07-22 | 1991-07-22 | |
US733033 | 1991-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0568631A1 EP0568631A1 (fr) | 1993-11-10 |
EP0568631A4 true EP0568631A4 (fr) | 1995-04-05 |
Family
ID=27094802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92905123A Withdrawn EP0568631A4 (fr) | 1991-01-24 | 1992-01-23 | Anticorps monoclonaux destines a un recepteur de surface cellulaire (elam-1) et utilisations de ces derniers. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0568631A4 (fr) |
JP (1) | JPH06505253A (fr) |
AU (1) | AU1269092A (fr) |
CA (1) | CA2100681A1 (fr) |
IE (1) | IE920206A1 (fr) |
IL (1) | IL100764A0 (fr) |
NO (1) | NO932672L (fr) |
NZ (1) | NZ241399A (fr) |
OA (1) | OA09809A (fr) |
SK (1) | SK77393A3 (fr) |
WO (1) | WO1992012729A1 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646123A (en) * | 1991-06-10 | 1997-07-08 | Alberta Research Council | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
ATE239506T1 (de) * | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US5648458A (en) * | 1992-05-06 | 1997-07-15 | Affymax Technologies N.V. | Peptides and compounds that bind to ELAM-1 |
US5728802A (en) * | 1992-05-06 | 1998-03-17 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1) |
US5643873A (en) * | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
EP0602290B1 (fr) * | 1992-12-04 | 1999-08-25 | ConjuChem, Inc. | Antigène de surface du virus de l'hépatite B conjugué à des anticorps et utilisation d'un tel conjugué |
US5723116A (en) * | 1995-01-06 | 1998-03-03 | University Of South Florida | Decreased mortality of severe acute pancreatitis following proximal cytokine blockade |
WO1996040942A1 (fr) * | 1995-06-07 | 1996-12-19 | Cytel Corporation | Anticorps humanises anti-e-selectine |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
BR9912053A (pt) | 1998-07-13 | 2001-04-03 | Univ Texas | Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
CN1356913A (zh) | 1998-12-18 | 2002-07-03 | 杜邦药品公司 | 玻连蛋白受体拮抗剂药物 |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
AU2371400A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
KR20110074850A (ko) * | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 길항제 및 그의 사용 방법 |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
KR20220131293A (ko) | 2020-01-24 | 2022-09-27 | 화이자 인코포레이티드 | 항-e-셀렉틴 항체, 조성물 및 사용 방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005786A1 (fr) * | 1988-11-14 | 1990-05-31 | Brigham And Women's Hospital | Genes clones codant elam-1 et leurs proteines de fusion, produits proteiques qui en sont exprimes, compositions pharmaceutiques et leur utilisation |
WO1990013300A1 (fr) * | 1989-04-28 | 1990-11-15 | Biogen, Inc. | Molecules d'adhesion leucocytes-cellules endotheliales (elam) et molecules impliquees dans l'adhesion des leucocytes (mila) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2002860A1 (fr) * | 1988-11-14 | 1990-05-14 | Michael A. Gimbrone | Anticorps specifiques de l'elam-1 et application |
-
1992
- 1992-01-23 SK SK773-93A patent/SK77393A3/sk unknown
- 1992-01-23 CA CA002100681A patent/CA2100681A1/fr not_active Abandoned
- 1992-01-23 IE IE020692A patent/IE920206A1/en not_active Application Discontinuation
- 1992-01-23 WO PCT/US1992/000577 patent/WO1992012729A1/fr not_active Application Discontinuation
- 1992-01-23 AU AU12690/92A patent/AU1269092A/en not_active Abandoned
- 1992-01-23 EP EP92905123A patent/EP0568631A4/fr not_active Withdrawn
- 1992-01-23 JP JP4505427A patent/JPH06505253A/ja active Pending
- 1992-01-24 NZ NZ241399A patent/NZ241399A/en unknown
- 1992-01-24 IL IL100764A patent/IL100764A0/xx unknown
-
1993
- 1993-07-22 OA OA60394A patent/OA09809A/en unknown
- 1993-07-23 NO NO93932672A patent/NO932672L/no unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005786A1 (fr) * | 1988-11-14 | 1990-05-31 | Brigham And Women's Hospital | Genes clones codant elam-1 et leurs proteines de fusion, produits proteiques qui en sont exprimes, compositions pharmaceutiques et leur utilisation |
WO1990013300A1 (fr) * | 1989-04-28 | 1990-11-15 | Biogen, Inc. | Molecules d'adhesion leucocytes-cellules endotheliales (elam) et molecules impliquees dans l'adhesion des leucocytes (mila) |
Non-Patent Citations (5)
Title |
---|
C. BENJAMIN ET AL.: "A blocking monoclonal antibody to endothelial-leukocyte adhesion molecule-1 (ELAM1).", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 171, no. 1, 31 August 1990 (1990-08-31), DULUTH MN, USA, pages 348 - 353 * |
M. BEVILACQUA ET AL.: "Identification of an inducible endothelial-leukocyte adhesion molecule.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 84, no. 24, December 1987 (1987-12-01), WASHINGTON DC, USA, pages 9238 - 9242 * |
N. GRABER ET AL.: "T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1.", THE JOURNAL OF IMMUNOLOGY, vol. 145, no. 3, 1 August 1990 (1990-08-01), BALTIMORE MD, USA, pages 819 - 830 * |
S. WELLICOME ET AL.: "A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide.", THE JOURNAL OF IMMUNOLOGY, vol. 144, no. 7, 1 April 1990 (1990-04-01), BALTIMORE MD, USA, pages 2558 - 2565 * |
See also references of WO9212729A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2100681A1 (fr) | 1992-07-25 |
AU1269092A (en) | 1992-08-27 |
SK77393A3 (en) | 1994-12-07 |
NO932672L (no) | 1993-09-23 |
IL100764A0 (en) | 1992-09-06 |
NZ241399A (en) | 1994-06-27 |
JPH06505253A (ja) | 1994-06-16 |
IE920206A1 (en) | 1992-07-29 |
WO1992012729A1 (fr) | 1992-08-06 |
EP0568631A1 (fr) | 1993-11-10 |
OA09809A (en) | 1994-04-15 |
NO932672D0 (no) | 1993-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0568631A4 (fr) | Anticorps monoclonaux destines a un recepteur de surface cellulaire (elam-1) et utilisations de ces derniers. | |
EP0627932A4 (fr) | Nouvelle structure d'anticorps. | |
IL101690A0 (en) | Antibodies and methods utilizing the same | |
SG48420A1 (en) | Humanized antibodies and uses thereof | |
GB9412166D0 (en) | Retargetting antibodies | |
EP0580859A4 (en) | Anti-eda monoclonal antibody | |
EP0804235A4 (fr) | Anticorps diriges contre la selectine p et leurs utilisations | |
EP0683675A4 (fr) | Anticorps monoclonaux humains contre le cytomegalovirus. | |
ZA898777B (en) | Monoclonal antibodies | |
EP0285511A3 (en) | Monoclonal antibodies and their uses | |
EP0506523A3 (en) | Monoclonal antibodies | |
GB9204928D0 (en) | Monoclonal antibody production | |
ZA898499B (en) | Anti-fucosylcermiade monoclonal antibody | |
GB2309459B (en) | Antibodies to fungal antigens | |
ZA92468B (en) | Monoclonal antibodies to ELAM-1 and their uses | |
GB9223676D0 (en) | Modified antibodies | |
GB2207921B (en) | Monoclonal antibody to omega-gliadin and hybridoma thereof | |
HU9503156D0 (en) | Antibodies to p-selectin and their uses | |
EP0547631A3 (en) | Antibody expression vector and antibodies produced thereby | |
EP0654532A4 (fr) | Anticorps monoclonal antimucoglycoproteine. | |
ZA912136B (en) | Anti-oncostatin m monoclonal antibodies | |
GB9115010D0 (en) | Antibody | |
EP0336441A3 (en) | Anti-cpbii monoclonal antibody | |
GB9118013D0 (en) | Monoclonal antibodies and their use | |
IE900593L (en) | Monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930813 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
RHK1 | Main classification (correction) |
Ipc: A61K 39/395 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19950215 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL |
|
17Q | First examination report despatched |
Effective date: 19970411 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19970822 |